A creative approach to managing a case of haemophilia A with inhibitors in a low-resource country: case report

1. Pinto P, Shelar T, Nawadkar V, et al. The epidemiology of FVIII Inhibitors in Indian haemophilia A patients. Indian J Hematol Blood Transfus 2014; 30(4): 356-63. doi: 10.1007/s12288-014-0342-z. Pinto P Shelar T Nawadkar V The epidemiology of FVIII Inhibitors in Indian haemophilia A patients . Indian J Hematol Blood Transfus 2014 ; 30 ( 4 ): 356 - 63 . doi: 10.1007/s12288-014-0342-z . Open DOISearch in Google Scholar

2. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26(S6): 1-158. doi: 10.1111/hae.14046. Srivastava A Santagostino E Dougall A WFH Guidelines for the Management of Hemophilia , 3rd edition. Haemophilia 2020 ; 26 ( S6 ): 1 - 158 . doi: 10.1111/hae.14046 . Open DOISearch in Google Scholar

3. Pratt KP, Arruda VR, Lacroix-Desmazes S. Inhibitors – Recent insights. Haemophilia 2021; 27 Suppl 3: 28-36. doi: 10.1111/hae.14077. Pratt KP Arruda VR Lacroix-Desmazes S . Inhibitors – Recent insights . Haemophilia 2021 ; 27 Suppl 3 : 28 - 36 . doi: 10.1111/hae.14077 . Open DOISearch in Google Scholar

4. Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374(21): 2054-64. doi: 10.1056/NEJMoa1516437. Peyvandi F Mannucci PM Garagiola I A randomized trial of factor VIII and neutralizing antibodies in hemophilia A . N Engl J Med 2016 ; 374 ( 21 ): 2054 - 64 . doi: 10.1056/NEJMoa1516437 . Open DOISearch in Google Scholar

5. Sachdeva A, Gunasekaran V, Ramya HN, et al. Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia. Indian Pediatr 2018; 55(7): 582-90. doi: 10.1007/s13312-018-1302-8. Sachdeva A Gunasekaran V Ramya HN Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia . Indian Pediatr 2018 ; 55 ( 7 ): 582 - 90 . doi: 10.1007/s13312-018-1302-8 . Open DOISearch in Google Scholar

6. Phadke S. Hemophilia care in India: a review and experience from a tertiary care centre in Uttar Pradesh. Indian J Hematol Blood Transfus 2011; 27(3): 121-6. doi: 10.1007/s12288-011-0084-0. Phadke S . Hemophilia care in India: a review and experience from a tertiary care centre in Uttar Pradesh . Indian J Hematol Blood Transfus 2011 ; 27 ( 3 ): 121 - 6 . doi: 10.1007/s12288-011-0084-0 . Open DOISearch in Google Scholar

7. Rangarajan S, Austin S, Goddard NJ, et al. Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery. Haemophilia 2013; 19(2): 294-303. doi: 10.1111/hae.12028. Rangarajan S Austin S Goddard NJ Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery . Haemophilia 2013 ; 19 ( 2 ): 294 - 303 . doi: 10.1111/hae.12028 . Open DOISearch in Google Scholar

8. Ghosh K, Shetty S, Kulkarni B, et al. Development of inhibitors in patients with haemophilia from India. Haemophilia 2001; 7(3): 273-8. doi: 10.1046/j.1365-2516.2001.00505.x. Ghosh K Shetty S Kulkarni B Development of inhibitors in patients with haemophilia from India . Haemophilia 2001 ; 7 ( 3 ): 273 - 8 . doi: 10.1046/j.1365-2516.2001.00505.x . Open DOISearch in Google Scholar

9. Kumar S, Sinha S, Bharti A, Meena LP, Gupta V, Shukla J. A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in North Eastern part of India. J Family Med Prim Care 2019; 8(7): 2463-7. doi: 10.4103/jfmpc.jfmpc_316_19. Kumar S Sinha S Bharti A Meena LP Gupta V Shukla J . A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in North Eastern part of India . J Family Med Prim Care 2019 ; 8 ( 7 ): 2463 - 7 . doi: 10.4103/jfmpc.jfmpc_316_19 . Open DOISearch in Google Scholar

10. Shah S, Patel T, Bhatnagar N, Gajjar M, Shah M, Tripathi S. “Prevalence of Inhibitors in Hemophilia Patients and its Clinical Implications”: A study of 276 patients in Western India. Global Journal of Transfusion Medicine 2019; 4(2): 168. doi: 10.4103/GJTM.GJTM_35_19. Shah S Patel T Bhatnagar N Gajjar M Shah M Tripathi S . “Prevalence of Inhibitors in Hemophilia Patients and its Clinical Implications”: A study of 276 patients in Western India . Global Journal of Transfusion Medicine 2019 ; 4 ( 2 ): 168 . doi: 10.4103/GJTM.GJTM_35_19 . Open DOISearch in Google Scholar

11. Lichtman M, Kaushansky K, Prchal J, Levi M, Burns L, Linch DC. Williams Manual of Hematology, 10th edn. 2022. Columbus, OH: McGraw-Hill Education. Lichtman M Kaushansky K Prchal J Levi M Burns L Linch DC . Williams Manual of Hematology , 10th edn. 2022 . Columbus, OH : McGraw-Hill Education . Search in Google Scholar

12. Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia 2010; 16(102): 20-4. doi: 10.1111/j.1365-2516.2008.01924.x. Verbruggen B . Diagnosis and quantification of factor VIII inhibitors . Haemophilia 2010 ; 16 ( 102 ): 20 - 4 . doi: 10.1111/j.1365-2516.2008.01924.x . Open DOISearch in Google Scholar

13. Jadhav U, Mukherjee K, Lalwani A. Ethical issues in the care of persons living with haemophilia in India. Indian J Med Ethics 2014; 11(4): 223-7. doi: 10.20529/IJME.2014.056. Jadhav U Mukherjee K Lalwani A . Ethical issues in the care of persons living with haemophilia in India . Indian J Med Ethics 2014 ; 11 ( 4 ): 223 - 7 . doi: 10.20529/IJME.2014.056 . Open DOISearch in Google Scholar

14. Per capita national income across India from financial year 2015 to 2018, with estimates until 2023. Statista. 23 August 2023. Available from: https://www.statista.com/statistics/802122/india-net-national-income-per-capita/ (accessed 14 September 2023). Per capita national income across India from financial year 2015 to 2018, with estimates until 2023 . Statista . 23 August 2023 . Available from: https://www.statista.com/statistics/802122/india-net-national-income-per-capita/ ( accessed 14 September 2023 ). Search in Google Scholar

15. Malkan UY, Aksu S. Combination of NovoSeven and FEIBA in hemophiliac patients with inhibitors. Open Med (Wars) 2018; 13: 618-21. doi: 10.1515/med-2018-0090. Malkan UY Aksu S . Combination of NovoSeven and FEIBA in hemophiliac patients with inhibitors . Open Med (Wars) 2018 ; 13 : 618 - 21 . doi: 10.1515/med-2018-0090 . Open DOISearch in Google Scholar

16. Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: The ups and downs of treatment. Blood Rev 2021; 50: 100852. doi: 10.1016/j. blre.2021.100852. Berntorp E Hermans C Solms A Poulsen L Mancuso ME . Optimising prophylaxis in haemophilia A: The ups and downs of treatment . Blood Rev 2021 ; 50 : 100852 . doi: 10.1016/j. blre.2021.100852 . Open DOISearch in Google Scholar

17. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med 2018; 379(9): 811-22. doi: 10.1056/NEJMoa1803550. Mahlangu J Oldenburg J Paz-Priel I Emicizumab prophylaxis in patients who have hemophilia a without inhibitors . N Engl J Med 2018 ; 379 ( 9 ): 811 - 22 . doi: 10.1056/NEJMoa1803550 . Open DOISearch in Google Scholar

18. Linari S, Castaman G. Concomitant use of rFVIIa and emicizumab in people with hemophilia A with inhibitors: current perspectives and emerging clinical evidence. Ther Clin Risk Manag 2020; 16: 461-9. doi: 10.2147/TCRM.S205310. Linari S Castaman G . Concomitant use of rFVIIa and emicizumab in people with hemophilia A with inhibitors: current perspectives and emerging clinical evidence . Ther Clin Risk Manag 2020 ; 16 : 461 - 9 . doi: 10.2147/TCRM.S205310 . Open DOISearch in Google Scholar

19. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 2004; 10 Suppl 2: 3-9. doi: 10.1111/j.1365-2516.2004.00934.x. Turecek PL Váradi K Gritsch H Schwarz HP . FEIBA: mode of action . Haemophilia 2004 ; 10 Suppl 2 : 3 - 9 . doi: 10.1111/j.1365-2516.2004.00934.x . Open DOISearch in Google Scholar

20. Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 2018; 24(3): 344-7. doi: 10.1111/hae.13495. Collins PW Liesner R Makris M Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee . Haemophilia 2018 ; 24 ( 3 ): 344 - 7 . doi: 10.1111/hae.13495 . Open DOISearch in Google Scholar

21. Hayashi T, Tanaka I, Shima M, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10(4): 397-400. doi: 10.1111/j.1365-2516.2004.00924.x. Hayashi T Tanaka I Shima M Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor . Haemophilia 2004 ; 10 ( 4 ): 397 - 400 . doi: 10.1111/j.1365-2516.2004.00924.x . Open DOISearch in Google Scholar

22. Kizilocak H, Marquez-Casas E, Malvar J, Young G. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab. Haemophilia 2023; 29(1): 100-5. doi: 10.1111/hae.14684. Kizilocak H Marquez-Casas E Malvar J Young G . Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab . Haemophilia 2023 ; 29 ( 1 ): 100 - 5 . doi: 10.1111/hae.14684 . Open DOISearch in Google Scholar

23. Radhakrishnan N, Shankar R, Maji M, Rana M. Initial experience of Emicizumab prophylaxis in children with inhibitor positive severe hemophilia A from a single center in India. Pediatric Hematology Oncology Journal 2021; 6(2):97-9. doi: 10.1016/j. phoj.2021.03.004. Radhakrishnan N Shankar R Maji M Rana M . Initial experience of Emicizumab prophylaxis in children with inhibitor positive severe hemophilia A from a single center in India . Pediatric Hematology Oncology Journal 2021 ; 6 ( 2 ): 97 - 9 . doi: 10.1016/j. phoj.2021.03.004 . Open DOISearch in Google Scholar